FDA seeks new advisory committee members, signaling renewed focus on external expertise

The FDA announced it is inviting subject‑matter experts and consumer representatives to serve on its advisory committees.

The call follows a period when the advisory committees had a reduced role under the previous administration, and the agency says it wants to broaden external input.

At the same time, stakeholders are reviewing the agency’s draft guidance on using single pivotal trials with confirmatory evidence for drug approvals, seeking clearer definitions of evidentiary standards.